Menopause – Medxy AI

Disparities and Persistence in Systemic Hormone Therapy Among Menopausal Women: Insights from a Large Real-World Analysis

By MedXY 07/31/2026

A comprehensive study reveals initiation rates, duration, and racial disparities in systemic hormone therapy use among menopausal women, emphasizing critical care gaps and the need for equitable interventions.

news OB/GYN & Women’s Health Oncology

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

By MedXY 07/20/2026

Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased oncologic harm.

news OB/GYN & Women’s Health Radiology

Fibroids Do Not Uniformly Regress After Menopause: Reframing Leiomyoma Care Across the Menopausal Transition

By MedXY 06/08/2026

A contemporary review shows that uterine leiomyomas often persist across menopause, requiring symptom-driven evaluation, structured imaging, and individualized management rather than assumptions of spontaneous regression.

Gastroenterology news OB/GYN & Women’s Health

Postmarketing Data Link Fezolinetant Primarily to Early Transaminase Elevations Rather Than Overt Liver Injury

By MedXY 06/01/2026

FAERS postmarketing data suggest fezolinetant is associated with an early hepatic adverse event reporting signal, driven mainly by liver enzyme elevations rather than consistent severe clinical liver injury.

news OB/GYN & Women’s Health Public Health

Menopausal Hot Flushes and Night Sweats May Be Linked to Retirement: What an Australian Study Found

By MedXY 05/13/2026

A large Australian longitudinal study found that women with both hot flushes and night sweats had slightly higher odds of retirement, suggesting menopausal symptom burden may influence workforce participation.

news OB/GYN & Women's Health Public Health

Earlier Menopause Linked to Accelerated Multimorbidity Progression: UK Biobank Multi-State Analysis Reveals Critical Windows for Preventive Intervention

By MedXY 04/06/2026

A large UK Biobank cohort study of 121,017 postmenopausal women reveals that earlier menopause significantly increases risks of multimorbidity progression, with women experiencing premature menopause facing 32% higher risk of developing first chronic disease and 22% higher risk of progressing to multimorbidity compared to those with menopause after age 50.

Diabetes & Endocrinology news

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

By MedXY 03/12/2026

A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for long-term management during the menopause transition.

news Oncology

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

By MedXY 02/06/2026

A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeeding and oral contraceptives appear specific to premenopausal women.

Cardiology news

Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks

By MedXY 12/16/2025

Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.

Clinical Updates news OB/GYN & Women's Health

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

By MedXY 11/13/2025

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.

news OB/GYN & Women's Health

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

By MedXY 11/13/2025

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.

OB/GYN & Women's Health

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

By MedXY 10/24/2025

Bayer's Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable safety in phase 3 trials.

Allergy & Immunology Clinical Updates news OB/GYN & Women's Health Specialties

Menopause and Multiple Sclerosis: Evaluating the Impact on Disability Progression

By MedXY 09/29/2025

A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging's role in disease trajectory.

Clinical Updates news OB/GYN & Women's Health Specialties

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY 09/07/2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.

Clinical Updates news OB/GYN & Women's Health Specialties

Estradiol Hormone Therapy Route Influences Memory Types in Postmenopausal Women

By MedXY 09/03/2025

Estradiol-based hormone therapy's impact on memory varies by administration route—with transdermal delivery linked to better episodic memory and oral delivery to improved prospective memory. Earlier menopause onset correlates with poorer cognitive performance.

OB/GYN & Women's Health Specialties

Unraveling Menopause: Symptom Prevalence and Severity Across the Transition—Insights from the Australian Women’s Midlife Years (AMY) Study

By MedXY 08/22/2025

The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reproductive stages.

AI news OB/GYN & Women's Health Specialties

Evaluating Digital Therapeutics for Midlife Women’s Menopausal Symptoms: A Synthesis of Recent Randomized Controlled Trials

By MedXY 08/20/2025

This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.

Clinical Updates news OB/GYN & Women's Health Specialties

Long-Term Fracture Risk After Menopausal Hormone Therapy: New Insights from a Landmark Study

By MedXY 07/30/2025

Large-scale UK data reveal a transient increase but sustained long-term reduction in fracture risk after discontinuing menopausal HRT, challenging prior assumptions and guiding future clinical decisions.

news OB/GYN & Women's Health Specialties

Rethinking Menopausal Hormone Therapy: Experts Urge FDA to Revise Outdated Warnings

By MedXY 07/29/2025

Leading experts call on the FDA to update boxed warnings on menopausal hormone therapies, arguing current labels are outdated and deter women from effective, safe treatments.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Weight Loss for Menopausal Women: The Role of Tirzepatide and Hormone Therapy

By MedXY 07/29/2025

A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.